2
Clinical Trials associated with EBX-102Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
The goal of this clinical trial is to test the ability to restore gut microbiota to healthier levels in patients with blood cancers scheduled to have stem cell transplant.
The main questions it aims to answer are:
Tolerability and acceptability of intestinal microbiota transplantation (IMT) versus placebo (as assessed via patient perspective questionnaires
Changes in gut microbiome diversity across all timepoints
Markers of general health, infective/microbiological and haematological outcomes including, days of fever, admission to intensive care unit, survival, non-relapsed mortality, and incidence of graft-versus-host disease across all time points measured.
Participants will be asked at their routine follow up visits to,
Provide stool, urine and blood samples at the scheduled study visits
Complete questionnaires at selected visits
Swallow either Placebo or IMT capsules once at the second study visit which will occur 2 weeks prior to the stem cell transplant (+/-3 days)
Researchers will compare IMT capsules and Placebo to investigate the change in gut microbiota diversity.
A multicentre, randomised, double-blind placebo-controlled, phase II study to evaluate the safety, tolerability and dose of dried intestinal microbiota medicinal product EBX-102 in liver cirrhosis subjects (IMPuLCE)
100 Clinical Results associated with EBX-102
100 Translational Medicine associated with EBX-102
100 Patents (Medical) associated with EBX-102
100 Deals associated with EBX-102